SCHEMBL19226554

SCHEMBL19226554

CC(C)c1ccc(C(=O)N2CCC3(CCNCC3)C2)cc1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GABRD O14764 2/20 0.61
GABRA1 P14867 2/20 0.61
GABRB1 P18505 2/20 0.61
GABRA5 P31644 2/20 0.61
GABRA3 P34903 2/20 0.61
GABRA2 P47869 2/20 0.61
GABRB2 P47870 2/20 0.61
GABRA4 P48169 2/20 0.61
NAMPT P43490 5/20 0.56
MEN1 O00255 1/20 0.54
ALDH1A1 P00352 1/20 0.54
LMNA P02545 1/20 0.54
KMT2A Q03164 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
L3MBTL3 Q96JM7 2/20 0.52
L3MBTL1 Q9Y468 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19226555 0.92 L3MBTL3 (0.61) GABRDGABRA1GABRB1GABRA5GABRA3
SCHEMBL21078072 0.87 GABRD (0.61) GABRDGABRA1GABRB1GABRA5GABRA3
SCHEMBL21214364 0.85 NAMPT (0.59) GABRDGABRA1GABRB1GABRA5GABRA3
SCHEMBL16565828 0.85 GABRD (0.84) GABRDGABRA1GABRB1GABRA5GABRA3
SCHEMBL7170182 0.82 NAMPT (0.65) GABRDGABRA1GABRB1GABRA5GABRA3
SCHEMBL19226553 0.82 GABRD (0.61) GABRDGABRA1GABRB1GABRA5GABRA3
SCHEMBL17886812 0.82 HPGD (0.64) GABRDGABRA1GABRB1GABRA5GABRA3
SCHEMBL12015795 0.80 ALDH1A1 (0.71) GABRDGABRA1GABRB1GABRA5GABRA3
SCHEMBL21214328 0.80 ALDH1A1 (0.57) MEN1ALDH1A1LMNAKMT2ASMN1; SMN2
SCHEMBL21078037 0.80 GABRD (0.59) GABRDGABRA1GABRB1GABRA5GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9873709-B2 Triazolopyridine compounds, compositions and methods of use thereof GENENTECH, INC. (US) 2018-01-23 US disclosed
US-20170226132-A1 TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170226132-A1 TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF ABL1, JAK2, JAK1 GABRD 1304/4885GABRA1 1791/4885GABRB1 1612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.